Timothy A. Yap

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.4Author DataRank

Indexed papers

9in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 9 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3

Top 8%

2.7DataRank

Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Papers

Driven by 61 papers — median percentile 0. Top paper: “Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials”.

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3

Top 8%

2.7DataRank

Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.682

N/A

2.3DataRank · unranked

71 citations

Shannon N. Westin, Gloria Salvo, Abdulrazzak Zarifa, Mingxuan Xu, Timothy A. Yap +6 more

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

New England Journal of Medicine(2009)10.1056/nejmoa0900212

N/A

1.2DataRank · unranked

3622 citations

David S. Boss, Timothy A. Yap, Richard Turkington, Peijun Wu, Marja Mergui-Roelvink +14 more

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2824

N/A

0.656DataRank · unranked

22 citations

Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan +7 more

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

NAR Cancer(2022)10.1093/narcan/zcac014

Top 31%

0.652DataRank

Top 31%22 citations

Michael W. Lloyd, Jeffrey W. Grover, Nan Xiao, Sara Seepo, Sai Lakshmi Subramanian +95 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-17

N/A

0.217DataRank · unranked

3 citations

Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean +15 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3548

N/A

0DataRank · unranked

1 citations

Benjamin Garmezy, Timothy A. Yap, John Paul Shen, Fadl A. Zeineddine

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

JCO Precision Oncology(2022)10.1200/po.21.00456

N/A

0DataRank · unranked

30 citations

Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke +6 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2509

N/A

0DataRank · unranked

9 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0361

N/A

0DataRank · unranked

68 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0103

N/A

0DataRank · unranked

29 citations

Kurt W. Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q. Rizvi, Xiaofeng Zheng +11 more

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3629

N/A

0DataRank · unranked

21 citations

Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing +29 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer

Cancer(2023)10.1002/cncr.34724

N/A

0DataRank · unranked

9 citations

Kenna Shaw, Fengyi Jin, Shannon N. Westin, Timothy A. Yap, Deanna Glassman +9 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2564

N/A

0DataRank · unranked

4 citations

Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean, Ly M. Nguyen +14 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743.v1

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

(2023)10.1158/2159-8290.c.6679570

N/A

0DataRank · unranked

0 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1 -Deficient Cancers

Cancer Discovery(2024)10.1158/2159-8290.cd-23-1220

N/A

0DataRank · unranked

51 citations

Chao Mao, Amber D. Horbath, Yuelong Yan, Shirong Cai, Jun Yao +17 more

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2409

N/A

0DataRank · unranked

45 citations

Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, Marta Enderlin, Christine Hicking +6 more

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-1763

N/A

0DataRank · unranked

13 citations

Virginia Giuliani, Wei‐Lien Wang, Daniel J. McGrail, Christopher A. Bristow, Natalie Y.L. Ngoi +46 more

Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0761

N/A

0DataRank · unranked

3 citations

Ian M. Silverman, Victoria Rimkunas, Artur Veloso, Dominik Głodzik, Adrienne Johnson +16 more

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1233

N/A

0DataRank · unranked

1 citations

Kurt W. Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N. Kwong +16 more

Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications

JCO Precision Oncology(2024)10.1200/po.24.00204

N/A

0DataRank · unranked

2 citations

Ruth Plummer, Timothy A. Yap, Carlos Torrado

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1500

N/A

0DataRank · unranked

6 citations

David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger +17 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1918

N/A

0DataRank · unranked

3 citations

Gabriela Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A. Davidson, Jiang Liu +4 more

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

Cancer(2025)10.1002/cncr.35728

N/A

0DataRank · unranked

4 citations

Filip Janku, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Timothy A. Yap +8 more

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ESMO Open(2025)10.1016/j.esmoop.2025.104136

N/A

0DataRank · unranked

4 citations

Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, DD Karp +9 more

Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma

npj Precision Oncology(2025)10.1038/s41698-025-01025-1

N/A

0DataRank · unranked

3 citations

Ian M. Silverman, Adrienne Johnson, Chenfeng Meng, Joseph D. Schonhoft, Michal Zimmermann +10 more

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0884

N/A

0DataRank · unranked

1 citations

Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng +10 more

Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations

European Journal of Nuclear Medicine and Molecular Imaging(2025)10.1007/s00259-025-07595-3

N/A

0DataRank · unranked

1 citations

Jiansong Chen, Peng Wei, Franklin C. Wong, Timothy A. Yap, Lilie L. Lin +1 more

Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2–mutant tumors: Bridging science with the clinic

Cancer(2025)10.1002/cncr.35890

N/A

0DataRank · unranked

0 citations

Milind Javle, Timothy A. Yap, Elise F. Nassif

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations

ESMO Open(2025)10.1016/j.esmoop.2025.105895

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Hai T. Tran, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap +8 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors

Journal of Clinical Investigation(2020)10.1172/jci130445

N/A

0DataRank · unranked

106 citations

Lin Yang, Chen Wang, Zhao Wei, Zhenlin Ju, Wei Zhang +11 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Targeting the replication stress response through synthetic lethal strategies in cancer medicine

Trends in cancer(2021)10.1016/j.trecan.2021.06.002

N/A

0DataRank · unranked

95 citations

Melissa Pham, David S.P. Tan, Timothy A. Yap, Natalie Y.L. Ngoi

PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma

Nature Communications(2021)10.1038/s41467-021-24798-y

N/A

0DataRank · unranked

78 citations

Meredith A. Miller, Chiu-Yi Liu, Stella R. Hartono, Caleb A. Class, Christopher A. Bristow +33 more

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

Pharmacogenomics and Personalized Medicine(2021)10.2147/pgpm.s305068

N/A

0DataRank · unranked

56 citations

Justin T. Moyers, Alice Harbery, Igor Vivanco, Timothy A. Yap, Niamh Coleman

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises

Trends in cancer(2021)10.1016/j.trecan.2021.05.004

N/A

0DataRank · unranked

37 citations

Natalie Y.L. Ngoi, Guang Peng, David S.P. Tan, Timothy A. Yap, Melissa Pham

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

The Lancet Oncology(2021)10.1016/s1470-2045(21)00017-6

N/A

0DataRank · unranked

12 citations

Lillian L. Siu, Emiliano Calvo, Martijn P. Lolkema, Patricia LoRusso, Jean‐Charles Soria +5 more

1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1417

N/A

0DataRank · unranked

4 citations

Timothy A. Yap, Sarina A. Piha‐Paul, Patricia LoRusso, Siwen Hu‐Lieskovan, Christopher J. Shepherd +6 more

Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37563

N/A

0DataRank · unranked

6 citations

Suyu Liu, Timothy A. Yap, Ying Yuan, Minjeong Park

Timothy A. Yap

Indexed papers

Top data-sharing exemplar

Papers